IDH1 and central nervous system cancer: In a comparative study by James P. Solomon’s Department of Pathology and Laboratory Medicine (Weill Cornell Medicine, New York), 39 samples from glioma patients treated on the New York-Presbyterian Hospital (NYPH) campus between 2018 and 2023 were examined regarding IDH1/2 status.